ES2363011T3 - Antagonistas de leptina. - Google Patents

Antagonistas de leptina. Download PDF

Info

Publication number
ES2363011T3
ES2363011T3 ES05809259T ES05809259T ES2363011T3 ES 2363011 T3 ES2363011 T3 ES 2363011T3 ES 05809259 T ES05809259 T ES 05809259T ES 05809259 T ES05809259 T ES 05809259T ES 2363011 T3 ES2363011 T3 ES 2363011T3
Authority
ES
Spain
Prior art keywords
leptin
human
seq
amino acid
polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES05809259T
Other languages
English (en)
Spanish (es)
Inventor
Arieh Gertler
Isabelle Callebaut
Jean Djiane
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Université Pierre et Marie Curie
Institut National de la Recherche Agronomique
Yissum Research Development Co of Hebrew University of Jerusalem
Original Assignee
Université Pierre et Marie Curie
Institut National de la Recherche Agronomique
Yissum Research Development Co of Hebrew University of Jerusalem
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Université Pierre et Marie Curie, Institut National de la Recherche Agronomique, Yissum Research Development Co of Hebrew University of Jerusalem filed Critical Université Pierre et Marie Curie
Application granted granted Critical
Publication of ES2363011T3 publication Critical patent/ES2363011T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/5759—Products of obesity genes, e.g. leptin, obese (OB), tub, fat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Child & Adolescent Psychology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
ES05809259T 2004-11-26 2005-11-24 Antagonistas de leptina. Expired - Lifetime ES2363011T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US996607 1997-12-23
US10/996,607 US7307142B2 (en) 2004-11-26 2004-11-26 Leptin antagonists

Publications (1)

Publication Number Publication Date
ES2363011T3 true ES2363011T3 (es) 2011-07-18

Family

ID=36204374

Family Applications (1)

Application Number Title Priority Date Filing Date
ES05809259T Expired - Lifetime ES2363011T3 (es) 2004-11-26 2005-11-24 Antagonistas de leptina.

Country Status (8)

Country Link
US (1) US7307142B2 (enExample)
EP (1) EP1814986B1 (enExample)
JP (1) JP5113526B2 (enExample)
CN (1) CN101189335B (enExample)
AT (1) ATE498683T1 (enExample)
DE (1) DE602005026432D1 (enExample)
ES (1) ES2363011T3 (enExample)
WO (1) WO2006056987A2 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8227408B2 (en) * 2005-09-07 2012-07-24 Neurotez, Inc. Leptin as an anti-amyloidogenic biologic and methods for delaying the onset and reducing Alzheimer's disease-like pathology
KR20110028457A (ko) * 2008-05-21 2011-03-18 뉴로테즈 인코포레이티드 신경섬유 매듭과 연관된 신경변성 장애를 치료하는 방법
CA2742600A1 (en) * 2008-11-04 2010-05-14 Nikolaos Tezapsidis Leptin compositions and methods for treating progressive cognitive function disorders resulting from accumulation of neurofibrillary tangles and amlyoid beta
WO2010117785A1 (en) * 2009-03-31 2010-10-14 Temple University - Of The Commonwealth System Of Higher Education Leptin antagonist and methods of use
MX2012012229A (es) * 2010-04-22 2013-03-05 Yissum Res Dev Co Leptinas de alta afinidad y antagonistas de leptina.
WO2014024189A1 (en) * 2012-08-06 2014-02-13 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd Pegylated high affinity leptins with increased biological activity
IT1423968B1 (enExample) * 2014-04-28 2016-08-26
US10926006B2 (en) 2015-02-26 2021-02-23 Remodeless Cv Ltd Drug eluting stent
CA2977607A1 (en) 2015-02-26 2016-09-01 Jacob Schneiderman Methods and compositions relating to leptin antagonists
US11123461B2 (en) 2015-02-26 2021-09-21 Remodeless Cv Ltd Treatment of ischemia and reperfusion using leptin antagonist
CN104829707B (zh) * 2015-05-06 2017-12-19 广东省生物资源应用研究所 一条cd环和e螺旋区突变的瘦素活性肽及其编码基因和应用
CN104829708B (zh) * 2015-05-06 2017-11-28 广东省生物资源应用研究所 一条d螺旋区突变的瘦素活性肽及其编码基因和应用
WO2017013270A1 (en) 2015-07-23 2017-01-26 Universite De Strasbourg Use of leptin signaling inhibitor for protecting kidneys from patients having ciliopathy
MA45801B1 (fr) * 2016-11-08 2021-11-30 Regeneron Pharma Protéines de liaison à l'antigène qui sont des antagonistes du récepteur de leptine
SMT202500283T1 (it) 2018-04-06 2025-09-12 Regeneron Pharma Un anticorpo agonista del recettore della leptina da utilizzare per aumentare la massa ossea in un soggetto affetto da disfunzione metabolica o ipoleptinemia
CN113195532B (zh) 2018-12-18 2025-04-11 瑞泽恩制药公司 使用针对瘦素受体、gdf8和活化素a的拮抗剂增加体重和瘦肌肉质量的组合物和方法
WO2024050285A2 (en) * 2022-08-31 2024-03-07 The Board Of Trustees Of The Leland Stanford Junior University Leptin analogs for treating obesity and weight management

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6309853B1 (en) * 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
WO1997020933A2 (en) * 1995-12-06 1997-06-12 Schering Corporation MUTATIONAL VARIANTS OF MAMMALIAN Ob GENE PROTEINS
US20020160935A1 (en) * 2000-03-24 2002-10-31 Smithkline Beecham Plc Use of leptin antagonists for the treatment of diabetes
JP2001500869A (ja) * 1996-09-20 2001-01-23 ヘキスト、アクチェンゲゼルシャフト 第ii種糖尿病におけるインスリン耐性を治療するためのレプチンアンタゴニストの使用
CN1491232A (zh) * 2001-02-06 2004-04-21 Ĭ��ר�����޹�˾ 免疫原性减弱的经修饰肥胖蛋白

Also Published As

Publication number Publication date
WO2006056987A3 (en) 2006-08-24
EP1814986B1 (en) 2011-02-16
EP1814986A2 (en) 2007-08-08
CN101189335B (zh) 2012-01-11
WO2006056987A2 (en) 2006-06-01
ATE498683T1 (de) 2011-03-15
US7307142B2 (en) 2007-12-11
US20060154859A1 (en) 2006-07-13
CN101189335A (zh) 2008-05-28
JP2008521795A (ja) 2008-06-26
DE602005026432D1 (de) 2011-03-31
JP5113526B2 (ja) 2013-01-09

Similar Documents

Publication Publication Date Title
ES3058577T3 (en) Conjugated hepcidin mimetics for use in treating of polycythemia vera
EP1121155B1 (en) Site-directed dual pegylation of proteins
EP1814986B1 (en) Leptin antagonists
ES2901704T3 (es) Análogos de hepcidina y usos de los mismos
CN107849110B (zh) 选择性pyy化合物及其用途
JP2018021019A (ja) Peg化された組換えヒト成長ホルモン化合物
KR20150006059A (ko) 섬유모세포 성장 인자 21 변이체
US12226487B2 (en) Therapeutic derivatives of interleukin-22
JP2014516049A (ja) アミリンペプチドおよび誘導体ならびにそれらの使用
IL297375B2 (en) Controlled-release CNP agonists with low NPR–C binding
WO2014139994A1 (en) Growth hormone compounds
BG108125A (bg) Peg-конюгати на хепатоцитния растежен фактор (hgt-nk4)
KR100507796B1 (ko) 생체내 반감기가 증가된 peg-생리활성 폴리펩티드 동종이량체 결합체 및 이의 제조방법
WO2022238503A1 (en) Therapeutic derivatives of interleukin-22
US11045523B2 (en) Formulation of growth hormone albumin-binder conjugate
RU2530714C9 (ru) Пэгилированные соединения рекомбинантного гормона роста человека
EA048412B1 (ru) Конъюгированные миметики гепсидина
HK1179899B (en) Pegylated recombinant human growth hormone compounds
WO2024126708A1 (en) Synthetic cytokines derived from the il-6 family and their medical use